Pay in 4 interest-free payments of $5.03 Learn more
Ships within 48 hours · Estimated delivery Aug 11 - Aug 16
In the present post hoc analysis, the decreased risk of first occurrence of MACE associated with semaglutide treatment vs placebo demonstrated in SUSTAIN 6 [12] was comparable for both genders, and overall event rates were similar or lower for women than men
The use of general descriptive names, trade names, trademarks, and so forth in this publication, even if not specifically identified, does not imply that these names are not protected by the relevant laws and regulations
Liu J, Sun B, Yin H, Liu S
Your healthcare provider can help you weigh these risk factors against the potential benefits to determine if these medications align with your health goals
Improves glycemic control (HbA1c, fasting plasma glucose) in overweight/obese and type 2 diabetic populations 2
The analysis, which leveraged electronic medical record data from Truveta, involved 41,223 patients prescribed either tirzepatide or semaglutide
